Incanthera PLC (AQSE:INC), a specialist in dermatology and oncology, is nearing the conclusion of pivotal commercial deal discussions, according to commentary alongside its prelims.
"The primary focus of our team remains the completion of our combined formulation and delivery technology in a product that we aim to be the subject of a commercial deal," investors were told.
The firm has also made significant advancements in refining its dermatological product formula range.
On the infrastructure front, Incanthera has successfully manufactured its final product formula range, established key commercial relationships, and secured protection for its valuable intellectual property across global territories.
Incanthera posted a loss for the 12 months ended 30 June 2023 of £1.37 million.